The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of BridgeBio Pharma Inc (NASDAQ: BBIO) closed at $45.95 in the last session, up 2.54% from day before closing price of $44.81. In other words, the price has increased by $2.54 from its previous closing price. On the day, 2.66 million shares were traded. BBIO stock price reached its highest trading level at $46.145 during the session, while it also had its lowest trading level at $44.1.
Ratios:
We take a closer look at BBIO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.08 and its Current Ratio is at 5.19.
On July 21, 2025, Truist started tracking the stock assigning a Buy rating and target price of $66. On July 14, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $70.Jefferies initiated its Buy rating on July 14, 2025, with a $70 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 05 ’25 when Ellis Andrea sold 17,167 shares for $49.00 per share. The transaction valued at 841,183 led to the insider holds 18,589 shares of the business.
ANDREA ELLIS bought 17,167 shares of BBIO for $841,183 on Aug 05 ’25. On Jul 02 ’25, another insider, Kumar Neil, who serves as the Chief Executive Officer of the company, sold 40,000 shares for $42.73 each. As a result, the insider received 1,709,050 and left with 955,686 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBIO now has a Market Capitalization of 8784215040 and an Enterprise Value of 9895107584. For the stock, the TTM Price-to-Sale (P/S) ratio is 37.25. Its current Enterprise Value per Revenue stands at 41.962 whereas that against EBITDA is -15.864.
Stock Price History:
The Beta on a monthly basis for BBIO is 1.26, which has changed by 0.8808842 over the last 52 weeks, in comparison to a change of 0.18634176 over the same period for the S&P500. Over the past 52 weeks, BBIO has reached a high of $49.77, while it has fallen to a 52-week low of $21.72. The 50-Day Moving Average of the stock is 6.72%, while the 200-Day Moving Average is calculated to be 34.27%.
Shares Statistics:
According to the various share statistics, BBIO traded on average about 3.04M shares per day over the past 3-months and 3669390 shares per day over the past 10 days. A total of 191.16M shares are outstanding, with a floating share count of 161.96M. Insiders hold about 15.28% of the company’s shares, while institutions hold 83.92% stake in the company. Shares short for BBIO as of 1752537600 were 19475283 with a Short Ratio of 6.41, compared to 1749772800 on 21119414. Therefore, it implies a Short% of Shares Outstanding of 19475283 and a Short% of Float of 17.29.
Earnings Estimates
Currently, 3.0 analysts are dedicated to thoroughly evaluating and rating the performance of BridgeBio Pharma Inc (BBIO) in the stock market.The consensus estimate for the next quarter is -$0.9, with high estimates of -$0.87 and low estimates of -$0.94.
Analysts are recommending an EPS of between -$2.57 and -$3.82 for the fiscal current year, implying an average EPS of -$2.99. EPS for the following year is -$1.77, with 5.0 analysts recommending between -$1.01 and -$2.59.
Revenue Estimates
According to 15 analysts, the current quarter’s revenue is expected to be $110.62M. It ranges from a high estimate of $140.5M to a low estimate of $85.72M. As of the current estimate, BridgeBio Pharma Inc’s year-ago sales were $2.73MFor the next quarter, 15 analysts are estimating revenue of $128.23M. There is a high estimate of $177M for the next quarter, whereas the lowest estimate is $52.37M.
A total of 21 analysts have provided revenue estimates for BBIO’s current fiscal year. The highest revenue estimate was $545.13M, while the lowest revenue estimate was $340.65M, resulting in an average revenue estimate of $455.48M. In the same quarter a year ago, actual revenue was $221.9MBased on 19 analysts’ estimates, the company’s revenue will be $760.91M in the next fiscal year. The high estimate is $1.12B and the low estimate is $424.25M.
